SLN

Silence Therapeutics Plc ADR (SLN) | Rumor.io

Silence Therapeutics

SLN

Attention (50-day avg)0%

Attention rank (50-day avg)#1,065

Bullish sentiment (50-day avg)65%

Price to earnings ratio-5.92

Market capitalization696.1M

Earnings per share-1.29

Dividend yield (TTM)—

Revenue (annual)559K

Net income (annual)-88.6M

Social

What share of all stock conversation is about SLN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% new	0% +0	0% 0	0% +0

Aug 11

Silence Therapeutics' (SLN) Phase 2 results showed 88% of treated patients responded, with the company testing an RNA drug to treat polycythemia vera.
Analysts have raised their target price for SLN from $25 to $32, and some predict the stock could be in the $20s.
The company's data is considered "super impressive," and some traders are taking a bullish stance, with a "BUY" signal and a target price of $17.37.

Generated by AI

Sentiment

Of the messages about SLN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% 0	36.95% -62.54	72.74% -9.91
Bearish	0%	0% 0	63.05% +62.54	27.26% +9.91

Aug 10

The company has released positive data, with a significantly higher proportion of clinical responders on its treatment, compared to placebo.
The stock has seen a substantial price increase, up 65% pre-market, with some traders targeting a price of $25.50 or higher.
The company's execution and entry strategy have been praised by traders, with some celebrating their profits and considering adding to their positions.

Generated by AI

Topics

Of the messages about SLN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	40%	86.55%
Technical Analysis	—	—	60%	11.43%
Analysts	—	—	0%	1.79%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0.22%
Macro	—	—	0%	0%

Mar 13

Silence Therapeutics plc (SLN) announced positive topline 36-week data from its ongoing Phase 2 study of Zerlasiran in patients with high lipoprotein(a).
The study met its primary endpoint, and the data suggests potential as a treatment for cardiovascular disease.
SLN reported full-year 2023 financial results, including a 45% increase in revenue, and recent business highlights.

Generated by AI

Community

Of the messages about SLN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	11.24%	17.56%
Newcomers	100%	100%	88.76%	82.44%

Aug 11

The newcomer is impressed with the Phase 2 results of Silence Therapeutics' RNA drug, Divesiran, which showed an 88% response rate in patients with polycythemia vera.
The newcomer is focused on the potential of Silence Therapeutics' Divesiran to treat polycythemia vera, a blood disorder, and believes the company has a good opportunity here.
The newcomer is concerned about the potential dilution of shares if Silence Therapeutics prices its offering at the market price, which could lead to a significant drop in share value.

Generated by AI

News

Polycythemia Vera Market Size, Emerging Therapies, and Forecast Insights Through 2036 – DelveInsight | Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharma

5d agoBarchart.com

Also Discussed

Investors talking about SLN also mention

#	Name	Attention
1	American International Group, Inc.AIG	0%+0
2	Ecolab IncECL	0%+0
3	SS&C Technologies Holdings, Inc.SSNC	0%new
4	LGTY - Logility Supply Chain Solutions, Inc.	——
5	Neuphoria Therapeutics Inc.NEUP	0%0
6	Korea Electric Power Corporation Sponsored ADRKEP	0%0
7	Columbia India Consumer ETFINCO	0%0
8	Esco Technologies Inc.ESE	0%0
9	Voya Financial Inc.VOYA	0%new
10	Ionis Pharmaceuticals, Inc.IONS	0%new

Silence Therapeutics Plc ADR

Healthcare
Biotechnology

Silence Therapeutics Plc ADR is a biotechnology company focused on developing RNA-based medicines that use short interfering RNA, or siRNA, to regulate the activity of specific genes. Silence Therapeutics Plc ADR is working across hematology, cardiovascular disease, and rare diseases, with a pipeline that includes candidates designed to address blood disorders, complement-mediated renal conditions, and lipid-related cardiovascular conditions. The company’s research and development activities center on discovering and delivering novel RNA therapeutics that can silence disease-driving targets inside cells. Through its current product candidates and platform-driven approach, Silence Therapeutics Plc ADR plays a specialized role in the growing field of genetic medicine, where precision therapies are being developed for conditions with limited treatment options. The company is headquartered in London, United Kingdom.

Website

Location

72 Hammersmith Road

London, W14 8TH

United Kingdom

Social

What share of all stock conversation is about SLN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% new	0% +0	0% 0	0% +0

Aug 11

Silence Therapeutics' (SLN) Phase 2 results showed 88% of treated patients responded, with the company testing an RNA drug to treat polycythemia vera.
Analysts have raised their target price for SLN from $25 to $32, and some predict the stock could be in the $20s.
The company's data is considered "super impressive," and some traders are taking a bullish stance, with a "BUY" signal and a target price of $17.37.

Generated by AI

Sentiment

Of the messages about SLN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% 0	36.95% -62.54	72.74% -9.91
Bearish	0%	0% 0	63.05% +62.54	27.26% +9.91

Aug 10

The company has released positive data, with a significantly higher proportion of clinical responders on its treatment, compared to placebo.
The stock has seen a substantial price increase, up 65% pre-market, with some traders targeting a price of $25.50 or higher.
The company's execution and entry strategy have been praised by traders, with some celebrating their profits and considering adding to their positions.

Generated by AI

Topics

Of the messages about SLN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	40%	86.55%
Technical Analysis	—	—	60%	11.43%
Analysts	—	—	0%	1.79%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0.22%
Macro	—	—	0%	0%

Mar 13

Silence Therapeutics plc (SLN) announced positive topline 36-week data from its ongoing Phase 2 study of Zerlasiran in patients with high lipoprotein(a).
The study met its primary endpoint, and the data suggests potential as a treatment for cardiovascular disease.
SLN reported full-year 2023 financial results, including a 45% increase in revenue, and recent business highlights.

Generated by AI

Community

Of the messages about SLN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	11.24%	17.56%
Newcomers	100%	100%	88.76%	82.44%

Aug 11

The newcomer is impressed with the Phase 2 results of Silence Therapeutics' RNA drug, Divesiran, which showed an 88% response rate in patients with polycythemia vera.
The newcomer is focused on the potential of Silence Therapeutics' Divesiran to treat polycythemia vera, a blood disorder, and believes the company has a good opportunity here.
The newcomer is concerned about the potential dilution of shares if Silence Therapeutics prices its offering at the market price, which could lead to a significant drop in share value.

Generated by AI

Silence Therapeutics

Social

Aug 11

Aug 10

Mar 13

Aug 11

Polycythemia Vera Market Size, Emerging Therapies, and Forecast Insights Through 2036 – DelveInsight | Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharma

Silence Therapeutics at Morgan Stanley conference: divesiran drives focus

Silence Therapeutics at H.C. Wainwright conference: divesiran drives focus

Silence Therapeutics at Cantor healthcare conference: divesiran advances

TScan Reorganizes Pipeline Priorities, Implements Workforce Reduction

Silence Therapeutics to Participate in Three September Investor Conferences

Also Discussed

Silence Therapeutics Plc ADR

Company Information

Location

Social

Aug 11

Aug 10

Mar 13

Aug 11

Polycythemia Vera Market Size, Emerging Therapies, and Forecast Insights Through 2036 – DelveInsight | Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharma

Silence Therapeutics at Morgan Stanley conference: divesiran drives focus

Silence Therapeutics at H.C. Wainwright conference: divesiran drives focus

Silence Therapeutics at Cantor healthcare conference: divesiran advances

TScan Reorganizes Pipeline Priorities, Implements Workforce Reduction

Silence Therapeutics to Participate in Three September Investor Conferences

Also Discussed